Status:
TERMINATED
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
Lead Sponsor:
Asan Medical Center
Conditions:
Invasive Fungal Infection
Eligibility:
All Genders
15+ years
Brief Summary
Multiple factors are associated with a large variability in voriconazole exposure following standard dose administration, such as non-linear saturable pharmacokinetics, drug-drug interactions, liver d...
Detailed Description
The investigators are trying to establish that routine clinical practice for voriconazole therapeutic drug monitoring can improve the efficacy and safety outcomes. In Korean patients with hematologic...
Eligibility Criteria
Inclusion
- all items below
- male or female ≥ 15 years of age
- immunocompromised patients with hematologic disorders
- patients received voriconazole due to treat proven, probable invasive (pulmonary) aspergillosis
Exclusion
- severe hepatic dysfunction (t.bil, AST, ALT, ALP \> 5 x upper normal limit)
- who experienced hypersensitivity to azoles
- pregnant women
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01148160
Start Date
August 1 2010
End Date
April 1 2014
Last Update
April 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center, University of Ulsan College of Medicine
Seoul, South Korea, 138-736